Merck (MRK) says MK-7243, its sublingual allergy immunotherapy tablet, performed better than placebo over the course of the grass pollen season.
"Patients exhibited significant improvement in common allergy symptoms," a study investigator says.
Results on TCS (the sum of of the rhinoconjunctivitis daily symptom score and the daily medication score averaged): MK-7243 group demonstrated a 23% improvement versus placebo (P< .001).
The FDA is reviewing MRK's BLA for the tablets. (PR)